What Can We Help You Find?

Latest In Research

The good news is that treatment options for lung cancer patients are rapidly improving. In the last two years, more treatments have been approved by the United States Food and Drug Administration (FDA) for the treatment of lung cancer than had been approved in the prior ten years. New and life saving treatments, along with clinical trials, are happening rapidly and LCFA is committed to keeping you up to date on the latest, most hopeful and helpful, information.

12/4
2019

Treatment Refusal for Small Cell Lung Cancer

Treatment refusal for small cell lung cancer studied: Small-cell lung cancer (SCLC) accounts for about 15% of all lung cancers, and the disease is not associated with a great outcome rate, with a 5-year survival of only around 6%. But S…

12/4
2019

How Are We Failing Lung Cancer Patients so Miserably?

From Medscape Oncology Failing Lung Cancer Patients The medical community is failing lung cancer patients. We are doing an unconscionably poor job of delivering appropriate targeted therapies to our patients. That's the only conclusi…

11/19
2019

Liquid Biopsies and NSCLC

From LungCancerNews.org Liquid Biopsies and NSCLC Genomic analysis of plasma cell free DNA (cfDNA) using liquid biopsies has been adopted widely in academic cancer centers. (It has not necessarily been adopted as widely in community…

10/25
2019

Inadequate Lung Cancer Screening Guidelines for First Responders

From EurekAlert Lung Cancer Screening Guidelines for First Responders National lung cancer screening guidelines are inadequate to diagnose patients who contract lung cancer from occupational exposure, including first responders, acco…

10/25
2019

Liquid Biopsies and Molecular Testing in Lung Cancer

From Oncology Learning Network At the 2019 Perspectives in Thoracic Oncology meeting, Marc Ladanyi, MD, Chief of Molecular Diagnostics at Memorial Sloan Kettering Cancer Center (MSKCC), New York, spoke with Oncology Learning Network …

10/24
2019

Nasal-Swab Lung Cancer Test

From Fierce BioTech Nasal-swab tests, Veracyte’s latest tool for detecting lung cancer accurately divided patients with lung nodules into groups at high or low risk of having lung cancer—using only a nasal swab. The noninvasive t…

10/4
2019

Tecentriq: IMpower-ing results

From Globaldata Healthcare Interim results from the highly-anticipated Phase III IMpower110 study were presented at the recent European Society for Medical Oncology (ESMO 2019) conference. Results demonstrated that first-line treatm…

10/4
2019

MET Treatment Gets Breakthrough Designation

From Healio The FDA granted breakthrough therapy designation to tepotinib for treatment of patients with metastatic non-small cell lung cancer who harbor MET exon 14 skipping alterations and progressed after platinum-based cancer therap…

10/4
2019

RET Drug Shrinks Tumors in Trial

From Reuters Eli Lilly and Co’s LOXO-292, a experimental cancer drug the company acquired in January as part of its $8 billion takeover of Loxo Oncology, shrank tumors in nearly 70% of advanced lung cancer patients whose tumors carrie…

10/4
2019

I/O Imfinzi prolongs survival

From Reuters AstraZeneca’s cancer treatment Imfinzi has been shown to prolong survival in a particularly aggressive type of lung cancer by close to three months, as the British drugmaker holds its ground in a crowded field against riv…

Research is imperative to improve treatment and management of all diseases and that’s particularly true of lung cancer. It’s creation of new knowledge, it’s discovery. It’s how we learn how to improve management of symptoms, to improve survival. ~Dr. David Johnson